Stockpolly
Search
FBRX · NASDAQ · Biotechnology

Forte Biosciences (FBRX)

Develops the anti-CD122 antibody candidate FB102 for autoimmune and autoimmune-related diseases.

$76.99
At close0.00 (0.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
10681397161218252225
Research & development6446651391521200
433732333322
Selling & marketing000000000000
General & administrative403730333322
Other expenses0000000000022
Operating income−10−6−8−13−9−7−16−12−18−25−22−25
010000001111
Interest income010001000000
Interest expense000000000000
Other non-operating income01000000−1−1−1−1
Income before tax−10−6−7−13−8−7−16−11−18−24−22−23
Income tax expense000000000100
Net income from continuing operations−10−6−7−13−8−7−16−11−18−25−22−23
Net income−10−6−7−13−8−7−16−11−18−25−22−23
EPS, basic−$6.57−$4.04−$4.77−$6.78−$4.54−$1.12−$1.37−$0.96−$0.99−$1.39−$1.24−$0.97
EPS, diluted−$6.57−$4.04−$4.77−$6.78−$4.54−$1.12−$1.37−$0.96−$0.99−$1.39−$1.24−$0.97
Weighted average shares, basic212226111218181824
Weighted average shares, diluted212226111218181824
EBITDA−10−7−7−13−8−7−16−11−18−24−22−23
Depreciation & amortization000000000000
EBIT−10−7−7−13−8−7−16−11−18−24−22−23